Devyser Diagnostics AB (publ) (STO:DVYSR)

Sweden flag Sweden · Delayed Price · Currency is SEK
88.50
+1.20 (1.37%)
Mar 6, 2026, 2:00 PM CET
-26.56%
Market Cap 1.45B
Revenue (ttm) 250.50M
Net Income (ttm) -8.40M
Shares Out 16.65M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE 35.52
Dividend n/a
Ex-Dividend Date n/a
Volume 7,125
Average Volume 31,904
Open 88.20
Previous Close 87.30
Day's Range 87.00 - 89.10
52-Week Range 83.30 - 159.60
Beta 0.61
RSI 32.56
Earnings Date Feb 12, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys... [Read more]

Sector Healthcare
Founded 2004
Employees 116
Stock Exchange Nasdaq Stockholm
Ticker Symbol DVYSR
Full Company Profile

Financial Performance

In 2025, Devyser Diagnostics AB's revenue was 250.50 million, an increase of 15.49% compared to the previous year's 216.90 million. Losses were -8.40 million, -86.34% less than in 2024.

Financial Statements

News

There is no news available yet.